Changes in estimated right ventricular systolic pressure predict mortality and pulmonary hypertension in a cohort of scleroderma patients

Annals of the Rheumatic Diseases

Volumn 72, Issue 7, 2013, Pages 1136-1140

  Shah, Ami A ^a   Chung, Shang En ^a   Wigley, Fredrick M ^a   Wise, Robert A ^a   Hummers, Laura K ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HEART CATHETERIZATION; HUMAN; LUNG DIFFUSION CAPACITY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREDICTION; PRESSURE MEASUREMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RIGHT VENTRICULAR SYSTOLIC BLOOD PRESSURE; RISK ASSESSMENT; RISK FACTOR; SCLERODERMA; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE;

CARDIOVASCULAR DISEASE; EPIDEMIOLOGY; SYSTEMIC SCLEROSIS;

ADULT; COHORT STUDIES; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SYSTOLE; VENTRICULAR PRESSURE;

EID: 84878401310     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201861     Document Type: Article

References (19)

1. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088-93. (Pubitemid 37323574)
2. Hachulla E, Carpentier P, Gressin V, et al. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study. Rheumatology (Oxford) 2009;48:304-8.
3. Mukerjee D, St George D, Knight C, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 2004;43:461-6. (Pubitemid 38489363)
4. Fischer A, Bull TM, Steen VD. Practical approach to screening for scleroderma-associated pulmonary arterial hypertension. Arthritis Care Res (Hoboken) 2012;64:303-10.
5. Chang B, Schachna L, White B, et al. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol 2006;33:269-74. (Pubitemid 43209302)
6. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003;48:516-22. (Pubitemid 36278021)
7. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
8. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5. (Pubitemid 18073738)
9. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 1999;159:179-87. (Pubitemid 29036522)
10. Knudson RJ, Kaltenborn WT, Knudson DE, et al. The single-breath carbon monoxide diffusing capacity. Reference equations derived from a healthy nonsmoking population and effects of hematocrit. Am Rev Respir Dis 1987;135:805-11. (Pubitemid 17055505)
11. Hsu VM, Moreyra AE, Wilson AC, et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 2008;35:458-65. (Pubitemid 351374421)
12. Fisher MR, Forfia PR, Chamera E, et al. Accuracy of doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009;179:615-21.
13. Kiatchoosakun S, Wongvipaporn C, Nanagara R, et al. Right ventricular systolic pressure assessed by echocardiography: a predictive factor of mortality in patients with scleroderma. Clin Cardiol 2011;34:488-93.
14. MacGregor AJ, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001;40:453-9.
15. Peters-Golden M, Wise RA, Hochberg MC, et al. Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis. Am J Med 1984;77:1027-34. (Pubitemid 15221764)
16. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792-800. (Pubitemid 41798217)
17. Schreiber BE, Valerio CJ, Keir GJ, et al. Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests. Arthritis Rheum 2011;63:3531-9.
18. Meune C, Avouac J, Airo P, et al. Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. Arthritis Rheum 2011;63:2790-6.
19. Wigley FM, Lima JA, Mayes M, et al. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005;52:2125-32. (Pubitemid 40994336)